Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980480 · ClinicalTrials.gov registry record · Phase 3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
A Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 183
- Enrollment target
- 16
- Study locations
NCT06980480: Recruiting Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency, sponsored by Takeda.
NCT06980480 is a Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency that is actively recruiting participants, run by Takeda. The registered enrollment target is 183 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06980480, a Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 183 participants
- Enrollment target
- 16
- Study locations
Study Summary
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy. Participants will be randomly assigned to one of two groups: 1. Primary infection prevention group: They will receive IGI, 10% for 12 months. 2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period. During the study, participants will visit their study clinic 15 times (for 4-week dosing interval) or 19 times (for 3-week dosing interval) and their total participation duration will be up to 14 months (including screening period of up to 8 weeks).
Conditions Studied
Interventions
- BIOLOGICAL IGI, 10%
Study Locations (16)
Other
- Universitaetsklinikum St. Poelten - Sankt Pölten
- Krankenhaus der Barmherzigen Schwestern Wien - Vienna
- St. Antonius Ziekenhuis - Nieuwegein
- Aidport sp. z o.o. - Skorzewo
- County Hospital (Stafford Hospital) - Stafford
Alabama
- Infirmary Health - Diagnostic & Medical Clinic (DMC) - Mobile
California
- Chao Family Comprehensive Cancer Center UCI - Orange
Kansas
- University of Kansas - Westwood
Maryland
- University of Maryland | Greenebaum Cancer Center - Baltimore
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University School of Medicine - St Louis
New York
- New York Oncology Hematology - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-09-11 |
| Phase | Phase 3 |
What NCT06980480 shows while recruiting
NCT06980480 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which IGI, 10% is the first listed.
NCT06980480 lists 16 locations in 12 states (Other, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT06980480 about?
NCT06980480 is a clinical study titled "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma". Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x clus...
What is the current status of trial NCT06980480?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2026-01-14. Estimated completion is 2028-09-11.
What conditions does trial NCT06980480 study?
This clinical trial studies the following conditions: Multiple Myeloma, Secondary Immunodeficiency.
What interventions are being tested in trial NCT06980480?
The interventions under investigation include: IGI, 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT06980480?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980480 being conducted?
This trial has 16 study locations across Alabama, California, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06980480's enrollment target sits among peer trials
183 118th of 438 higher than 321 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI